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Abstract The reversibility of non-genotoxic phenotyp-
ic changes has been explored in order to develop novel
preventive and therapeutic approaches for cancer.
Quisinostat (JNJ-26481585), a novel second-
generation histone deacetylase inhibitor (HDACi), has
efficient therapeutic actions on non-small cell lung can-
cer (NSCLC) cell. The present study aims at investigat-
ing underlying molecular mechanisms involved in the
therapeutic activity of quisinostat on NSCLC cells. We
found that quisinostat significantly inhibited A549 cell
proliferation in dose- and time-dependent manners. Up-
acetylation of histones H3 and H4 and non-histone
protein α-tubulin was induced by quisinostat treatment
in a nanomolar concentration. We also demonstrated
that quisinostat increased reactive oxygen species
(ROS) production and destroyed mitochondrial mem-
brane potential (ΔΨm), inducing mitochondria-
mediated cell apoptosis. Furthermore, exposure of
A549 cells to quisinostat significantly suppressed cell
migration by inhibiting epithelial-mesenchymal transi-
tion (EMT) process. Bioinformatics analysis indicated
that effects of quisinostat on NSCLC cells were associ-
ated with activated p53 signaling pathway. We found
that quisinostat increased p53 acetylation at K382/K373
sites, upregulated the expression of p21(Waf1/Cip1), and
resulted in G1 phase arrest. Thus, our results suggest
that the histone deacetylase can be a therapeutic target of
NSCLC to discover and develop a new category of
therapy for lung cancer.
Keywords Acetylation . Apoptosis . Epithelial-
mesenchymal transition .Mitochondria . p53 . Histone
deacetylase inhibitor
Introduction
Lung cancer is the leading cause of cancer-related mor-
tality worldwide with an incidence of about 1.5 million
people each year and an overall 5-year survival rate less
than 16 % (Tartour and Zitvogel 2013). According to
histological classifications, non-small cell lung cancer
(NSCLC) represents approximately 80 % of all lung
cancers. In the last decade, the major advance in the
treatment of NSCLC grew from the recognition that
specific genetic alterations define subsets of NSCLC
(Berge and Doebele 2014), such as epidermal growth
factor receptor (EGFR) mutations, Kirsten rat sarcoma
viral oncogene homolog (KRAS) mutations, and ana-
plastic lymphoma kinase (ALK) translocation, with a
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number of drugs targeting such specific oncogenes.
Despite these advancements, loss of treatment efficacy
with acquired resistance is becoming universal in
NSCLC patients treated with these targeted agents
(Camidge et al. 2014). New targets are therefore needed
to improve the efficacy of lung cancer therapy.
In addition to genetic alterations, epigenetic changes
may also contribute to the development and progression
of solid and hematologic malignancies (Lund 2004).
Generally speaking, acetylation modification of
Bhistone tails^ is the most extensively studied epigenetic
event, which regulates transcriptional activities and af-
fects biological processes and functions (Allfrey et al.
1964). Histone acetylation and deacetylation are con-
trolled by two classes of enzymes—histone acetyltrans-
ferases (HATs) and histone deacetylases (HDACs)
(Kurdistani and Grunstein 2003). HDACs are known
to be intimately related with the development and pro-
gression of cancers (Weichert 2009), including lung
cancer. It is reported that HDACs are frequently
overexpressed in lung cancer, and this overexpression
correlates with poor prognosis and drug resistance
(Osada et al. 2004). Thus, in contrast to genetic cancer
causes, HDACs and epigenetic changes may provide
new targets for therapeutic intervention in NSCLC.
Histone deacetylase inhibitors (HDACis) have
emerged as a novel class of anti-cancer agents that
regulate chromatin structure and gene expression, in-
ducing growth inhibition, apoptosis, and differentiation
in various tumor cells (Kelly and Marks 2005; Liu et al.
2006; Miller et al. 2011; Zhang and Zhong 2014).
HDACis significantly increase core histone acetylation,
resulting in increased expression of several genes that
are often silenced in cancer, such as tumor suppressor
genes (Liu et al. 2006). Despite histones, a wide variety
of non-histone proteins are also demonstrated to be
regulated by acetylation, which may contribute to the
anti-tumor effects of HDACi (Zhang and Zhong 2014).
In this study, we investigated the potential therapeutic
value of quisinostat (JNJ-26481585), a novel second-
generation HDACi, in NSCLC cells. In vitro,
quisinostat has shown anti-proliferative activity against
NSCLC cell lines (Arts et al. 2009), while the molecular
mechanisms are still unclear. Our results showed that
quisinostat extremely changed protein acetylation pat-
terns of A549 cells and inhibited epithelial-
mesenchymal transition (EMT) process. Exposure to
quisinostat induced mitochondrial injury and increased
p53 acetylation, resulting in cell apoptosis and G1 phase
arrest. In conclusion, these findings provide the proof of




Human NSCLC cell line A549 was obtained from the
Cell Bank of the Chinese Academy of Sciences
(Shanghai, China). Cells were cultured in high-glucose
DMEM (Gibco, Invitrogen, UK) containing 10 % fetal
bovine serum (FBS) (Gibco, Invitrogen, UK) and
100 U/ml of penicillin G/streptomycin. These cells were
cultured in an incubator at 37 °C in 5 % CO2 with a
humidified atmosphere.
Cell viability assay
Cell Counting Kit-8 (CCK-8) (Beyotime, China) was
utilized to evaluate cell viability of cells treated with
quisinostat (the chemical structure of quisinostat is
shown in Fig. 1a). The cell samples were exposed to
various concentrations of quisinostat for 24, 48, or 72 h.
After the end of incubation, the medium was removed
from each well, 10 μl of CCK-8 and 100 μl of serum-
free medium were added, and the cells then were incu-
bated for 1 h at 37 °C. The absorbance of each well was
measured at 450 nm using a microplate reader (Thermo
Fisher Scientific, USA). Each well was triplicate.
Wound healing experiment
Wound healing experiment was performed as described
previously (Lee et al. 2010). Photographs of the wound
area were captured at 0, 24, and 48 h with a microscope
(Nikon ECLIPSE TS100, Japan). Data were quantified
through analyzing the areas in the scratch not covered
by cells with ImageJ software version 1.49. Closure rate
was measured as percentage of the area at 0 h.
Cell migration experiment
Transwell chambers (Corning, NY, USA) were used in
cell migration experiments as described previously
(Chaulet et al. 2001). Cells were incubated at 37 °C
for 24 h, and cells that did not penetrate the polycarbon-
ate membrane at the bottom of the upper chamber were
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erased with cotton swabs. The cells that penetrated
through the membrane were fixed with methanol and
0.1 % crystal violet for 10 min at room temperature. The
stained crystal violet was eluted with 33 % acetic acid
solution. The optical density (OD) value of the solution
was detected with a microplate reader at 570 nm. The
migration activity was quantified by cell counter asso-
ciated with the OD value.
Intracellular ROS measurement
Intracellular reactive oxygen species (ROS) was mea-
sured by use of a 2′,7′-dichlorodihydrofluorescein
diacetate (DCFH-DA) probe (Sigma, USA). Pretreated
with various concentrations of quisinostat for 24 h,
A549 cells were exposed to serum-free medium con-
taining 10 μM DCFH-DA for 30 min in the darkness.
Then, the cells were washed with the medium for three
times, and fluorescent intensity was measured by flow
cytometry. Data were analyzed using FlowJo software
vesion 7.6.
Assessment of mitochondrial membrane potential
(ΔΨm)
Cells were stained with ΔΨm-sensitive probe JC-1
(5 , 5 ′ , 6 , 6 ′ - t e t r a ch l o r o -1 , 1 ′ , 3 , 3 ′ - t e t r a e t hy l -
imidacarbocyanine iodide) (Beyotime, China), at a final
concentration of 5 μg/ml in serum-free medium for
20 min at 37 °C in the darkness. After PBS washes,
JC-1-labeled cells were observed by a confocal micro-
scope (Olympus, USA) and harvested cells were ana-
lyzed by flow cytometry. Increased green fluorescence
and deceased red fluorescence of the cells were ob-
served as the mitochondrial membrane potential
collapsed.
Intracellular ATP measurement
To measure intracellular ATP levels, an ATP detection
kit (Beyotime, China) was used. Pretreated with
quisinostat for 24 h, A549 cells were analyzed following
the manufacturer’s instructions. The relative ATP level
was calculated according to the following formula: rel-
ative ATP level (nmol/mg) = ATP value (nmol/ml) / pro-
tein value (mg/ml).
Apoptosis analysis
Quisinostat-pretreated cells were trypsinized and
washed with complete medium. The samples (5 × 105
cells) were centrifuged for 5 min at 400×g, and the
supernatant was discarded. The cells were then stained
using an annexin V-fluorescein isothiocyanate (FITC)/
propidium iodide (PI) solution from apoptosis kit
(Beyotime, China) for 10 min in the darkness. The
number of apoptotic cells was detected and analyzed
using flow cytometry.
Gene expression profiling and bioinformatics analysis
Microarray experiments were carried out using the
Illumina BeadChip according to the manufacturer’s pro-
tocol. The raw data were analyzed using GenomeStudio
and normalized according to the quantile algorithm. A
two-tail t test, assuming unequal variance between the
Fig. 1 Effect of quisinostat on the viability of A549 cells. a
Chemical structure of quisinostat (JNJ-26481585). b A549 cells
were treated with series of quisinostat for 24, 48, or 72 h, and cell
viability was evaluated. Mean ± SD of three experiments per-
formed in triplicate is shown
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groups, was performed in order to determine signifi-
cance. p value of 0.05 and diffscore of 20 were used to
identify genes that were differentially expressed. Gene
ontology (GO) (Ashburner et al. 2000) enrichment anal-
ysis was performed on the significant genes using the
Database for Annotation, Visualization, and Integrated
Discovery (DAVID) bioinformatics online toolset (da
Huang et al. 2009). Additionally, enrichment was also
performed on pathways from the Kyoto Encyclopedia
of Genes and Genomes (KEGG) (Kanehisa et al. 2004).
Cell cycle analysis
We performed cell cycle analysis using PI (Sigma-
Aldrich) staining, followed by flow cytometry as previ-
ously described (Zhu et al. 2015). Data were evaluated
using ModFit LT version 3.1.
Real-time reverse transcription polymerase chain
reaction
Total RNA of A549 cells was extracted using TRIzol
( I nv i t r ogen , UK) fo l l ow ing the p ro toco l .
Complementary DNA (cDNA) was synthesized in ac-
cordance with the manufacturer’s instructions (Toyobo,
Japan). Quantitative normalization of cDNA in each
sample was performed using housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
as an internal control to determine the uniformity of the
template RNA for all specimens.
Western blot assay
After 24 h of treatment with quisinostat, the cells were
subjected to protein extraction. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and immunoblotting
were performed as previously described (Yu et al. 2015).
Statistical analysis
All data in this study were obtained from three indepen-
dent experiments and then expressed as the means
± standard deviation (SD). Student’s t test was used to
determine the difference between two groups. All the
analysis was performed on SPSS 17.0 software (SPSS,
IL, USA). The level of statistical significance was set at
p < 0.05.
Results
Quisinostat inhibited the viability of A549 cells
The CCK-8 assay was used to evaluate the impact of
quisinostat on cell viability. A549 cells were treated for
24, 48, or 72 h with quisinostat diluted to concentrations
of 5, 10, 20, 40, 60, 80, 100, 125, 250, and 500 nM in
complete medium. The results indicated that relative to
the control cells, A549 cell exposure to quisinostat for
24 h exhibited viability of 104.6, 104.0, 99.8, 93.3, 90.5,
87.5, 85.8, 85.3, 74.0, and 70.5 %, respectively; cells
treated for 48 h exhibited viability of 104.1, 98.4, 90.5,
74.8, 69.3, 48.6, 44.6, 30.0, 10.2, and 4.8 %, respective-
ly; and cells treated for 72 h exhibited viability of 103.6,
91.0, 81.9, 54.8, 33.0, 18.1, 12.1, 6.5, 1.6, and 1.2 %,
respectively (Fig. 1b). In addition, the IC50 values of
cells for 48 and 72 h of quisinostat treatment were 82.4
and 42.0 nM, respectively. The assay results suggested
that quisinostat extremely inhibited the proliferation of
A549 cells in dose- and time-dependent manners
(Fig. 1b). Meanwhile, we found that the viability of
A549 cells did not change significantly with the dosage
below 100 nM at 24-h time point. Therefore, the expo-
sure concentration of quisinostat lower than 100 nM
with exposure time at 24 h was chosen for further
experiments.
Quisinostat changed A549 protein acetylation patterns
and increased acetylation of histones and α-tubulin
To identify acetylated proteins, we analyzed the cell
lysates by western blot using gradient gel electrophore-
sis (4–20 %). After electrophoresis, the proteins were
t rans fe r red to PVDF membranes and then
immunoblotted with a pan-anti-acetyllysine monoclonal
antibody (Yu et al. 2015). As shown in Fig. 2a, the
antibody could detect the accumulation of acetylated
proteins induced in A549 cells by treating with
quisinostat. The differences in the density of the bands
are thought to reflect the differences in the levels of
protein acetylation. Although acetylated protein bands
could not be defined accurately, we found extreme
variation of acetylated patterns from quisinostat expo-
sure to control (Fig. 2a). The most salient acetylated
bands around 15-kDa position might be histones, which
is consistent with the reports describing their acetyla-
tions (Graff and Tsai 2013). Another detected bands
appeared at about 55 kDa; these acetylated proteins
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might be α-tubulin (Song and Brady 2015). The other
bands should be further studied.
To validate our guess that quisinostat increased acet-
ylation of histones and α-tubulin in A549 cells, we
further detected these proteins using specific anti-
acetylation antibodies. We found acetylation status of
histones H3 and H4, and α-tubulin (K40) was signifi-
cantly increased in a dose-dependent manner (Fig. 2b),
which was consistent with our guess.
Quisinostat inhibited A549 cell migration
by suppressing EMT process
Wound healing experiment was performed to evaluate
the effect of quisinostat on A549 cell migration. As
shown in Fig. 3a, b, more than half of the wound area
in control groupwas recovered with cell monolayer after
48-h incubation compared with 0 h. The closure rates of
groups treated with quisinostat at 50 and 100 nM were
59.92 ± 4.28 and 73.88 ± 5.12 %, respectively, which
were significantly inhibited to the control group with
48.96 ± 4.88 % (p < 0.01) (Fig. 3b). Furthermore, in
Transwell migration experiment, the number of migrat-
ing cells treated with quisinostat was significantly lower
than that of control cells after 24 h of being cultured
(Fig. 3c). The OD values of crystal violet suggested that
migrating cells treated with quisinostat at 25, 50, and
100 nM were 88.30 ± 4.02, 68.97 ± 2.68, and 55.50
± 4.33 % of control group cells (p < 0.01) (Fig. 3d).
To define the mechanism of anti-migration effect of
quisinostat against A549 cells, we investigated the in-
volvement of several EMT process signs. EMT process
has been recognized as a key contributor in cancer cell
migration and metastasis (Guarino et al. 2007), which is
characterized by loss of cell adhesion, downregulation
of E-cadherin expression, and acquisition of mesenchy-
mal markers including N-cadherin and Vimentin to in-
crease cell motility (Guarino et al. 2007). The western
blot analysis data demonstrated that cells treated with
quisinostat for 24 h upregulated E-cadherin expression
(Fig. 3e) and downregulated N-cadherin and Vimentin
expressions (Fig. 3e), indicating that quisinostat signif-
icantly inhibited A549 cell EMT process.
Effects of quisinostat on the mitochondria
Mitochondria are important in cell functions, and in-
creasing evidences indicate that mitochondrial dysfunc-
tion is often involved in the induction of apoptosis (van
Loo et al. 2002). To assess the role of mitochondria in
anti-tumor effect of quisinostat, we tested whether mi-
tochondrialΔΨmwill be collapsed by quisinostat treat-
ment, which is an early marker of mitochondria-
mediated apoptosis. Confocal microscopy observations
showed that the red fluorescence was decreased and
green fluorescence was increased with quisinostat treat-
ment (Fig. 4c), indicating that mitochondrialΔΨm was
collapsed. Flow cytometry assay data also suggested
Fig. 2 Effect of quisinostat on protein acetylation patterns. a
A549 cells were treated with quisinostat for 24 h. Protein acetyla-
tion patterns were assessed by western blot (4–20 % gradient gel
electrophoresis) using pan-anti-acetyllysine antibody. bA549 cells
were treated with quisinostat for 24 h. Protein expression of
acetylated histone 3 (Ac-H3), total H3, acetylated histone 4 (Ac-
H4), total H4, acetylated α-tubulin (K40), α-tubulin, and β-actin
was assessed by western blot
Cell Biol Toxicol (2016) 32:469–482 473
that quisinostat caused an obvious decrease of ΔΨm in
A549 cells. The red/green ratios of groups treated with
quisinostat at 25, 50, and 100 nM were 95.46 ± 1.68,
87.60 ± 1.14, and 72.24 ± 3.40 %, respectively, com-
pared with the control group (Fig. 4d).
Mitochondrial ΔΨm loss is often accompanied by
the production of ROS (Vaux and Korsmeyer 1999). We
found that quisinostat significantly induced ROS release
in a dose-dependent manner (Fig. 4a, b). Cellular ATP
depletion is another marker of early apoptosis; our re-
sults showed that high concentration of quisinostat
significantly decreased intracellular ATP levels of
A549 cells (Fig. 4e). These data indicated that
quisinostat might trigger mitochondria-mediated apo-
ptosis by increasing ROS production and decreasing
ATP generation in A549 cells.
Quisinostat induced mitochondria-mediated apoptosis
To characterize quisinostat-induced apoptosis, A549
cells were stained with annexin V-FITC and PI and then
analyzed by flow cytometry. The result showed that
Fig. 3 Effects of quisinostat on A549 cell migration and EMT
process. a A549 cells were incubated in serum-free medium for
48 h, and cell migration was evaluated by wound healing assay
(×40). b The wound width of five random views was measured,
and the healing width was calculated. c Effect of quisinostat on
A549 cell migration in a ×100 light scope after crystal violet
staining by Transwell assay. d The absorbance of eluted crystal
violet was read at 570 nm on a microplate reader. e A549 cells
were treated with quisinostat for 24 h. Protein expression of E-
cadherin, N-cadherin, Vimentin, and GAPDH was assessed by
western blot. The results were obtained from triplicate experiments
and represented as means ± SD (n = 3). *p < 0.05 and **p < 0.01
versus control group
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quisinostat increased apoptosis in A549 cells (Fig. 5a),
and the percentages of apoptotic cells of control and 25,
50, and 100 nM were 2.65 ± 0.19, 9.75 ± 0.06, 9.28
± 0.25, and 15.00 ± 0.17 %, respectively (Fig. 5b).
To define the molecular mechanisms, we investigated
the involvement of Bcl-2 family proteins and caspase
family proteins during the induction of cell apoptosis by
quisinostat in A549 cells. We found that exposure to
quisinostat resulted in a marked decrease in protein
expressions of anti-apoptotic proteins Bcl-2 and Bcl-xl
(Fig. 5c) and a drastic increase of pro-apoptotic proteins
Bax and Bim (Fig. 5c) as well as cleaved caspase-9 and
cleaved caspase-3 proteins (Fig. 5c). Moreover, we also
found that Cyto c was significantly upregulated
(Fig. 5c), which is involved in mitochondria-mediated
apoptosis.
Bioinformatics analysis indicated that quisinostat was
involved in p53 signaling pathway activation
To search for the pathways affected by quisinostat treat-
ment, gene expression profiling was performed. After
data collecting and normalizing, we compared the genes
of quisinostat treatment group to controls followed by
Fig. 4 Effects of quisinostat on mitochondrial functions. a Rep-
resentative images of A549 cells treated with quisinostat for 24 h
versus normal and subjected to confocal microscopy of the DCFH-
DA dye staining, as well as counterstaining with Hoechst 33342
(which marks chromatin). The increased intensity of cell fluores-
cence caused by treatment with quisinostat indicates elevated ROS
production. b Flow cytometry analysis of intracellular ROS levels
in A549 cells labeled with DCFH-DA dye. c A549 cells were
treated with quisinostat for 24 h prior to JC-1 staining. Images
shown are representative observations from three independent
experiments. Red images indicate the JC-1 aggregate fluorescence
from healthy mitochondria, while green images exhibit cytosolic
JC-1 monomers. Merged images indicated the co-localization of
JC-1 aggregates and monomers. d Mitochondrial potential loss
assay by flow cytometry. e Effect of quisinostat on cellular ATP
levels. Data are shown as mean ± SD, n = 3. *p < 0.05, **p < 0.01
versus control group (Color figure online)
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diffscore. Selected genes were further analyzed by bio-
informatics methods including GO analysis and KEGG
pathway analysis. GO analysis demonstrated that
targeted genes were significantly enriched in cellular
metabolic process, mitotic cell cycle, and cell cycle
process in biological process (Fig. 6a); the terms of
molecular function include protein binding, RNA bind-
ing, and ATP binding (Fig. 6b). In KEGG pathway
analysis, similar terms were enriched, including DNA
replication and cell cycle (Fig. 6c). Interestingly, we
found that p53 signaling pathway was significantly
enriched (Fig. 6c). According to the profiling results,
the expression level of p53 was little changed, but many
downstream genes of p53 were significantly altered
(Supplement Fig. 1), indicating that p53 activity might
play a crucial role in quisinostat-induced anti-NSCLC
cells.
Acetylation is essential for p53 activation (Tang et al.
2008). Using western blot analysis, we detected p53
acetylation status in A549 cells by quisinostat treatment.
We found that after treatment with quisinostat, the acet-
ylation of p53 at K382/K373 sites was significantly
increased (Fig. 6d).
Quisinostat induced G1 phase arrest and upregulated
p21(Waf1/Cip1) expression
The gene expression profiling analysis indicated that
quisinostat might affect cell cycle of A549 cells. Our
results showed that the cell cycle distribution was mark-
edly changed with quisinostat treatment (Fig. 7a); the
amount of cells in G1 phase showed a significant in-
crease (Fig. 7b). To elucidate the mechanism behind the
induction of G1 phase arrest, we assessed the effect of
quisinostat on the induction of p21(Waf1/Cip1), p27, and
p57, the cyclin-dependent kinase (CDK) inhibitors,
which are known to regulate the entry of cells at the
G1-S phase transition checkpoint (Arts et al. 2009).
Fig. 5 Apoptosis of A549 cells in vitro. a The cell apoptosis was
determined by flow cytometry. The cells were treated with 25, 50,
and 100 nm of quisinostat for 24 h, and then, cells were
trypsinized, washed with PBS, and stained using an annexin
V/FITC kit. Fluorescence intensity for annexin V/FITC is plotted
on the x-axis, and PI is plotted on the y-axis. b Total annexin
V/FITC-positive cells were analyzed as death cells. Data are
shown as mean ± SD, n = 3. **p < 0.01 versus control group. c
Protein expression of Bax, Bim, Bcl-xl, Bcl-2, Cyto c, cleaved
caspase-9 (Cleaved-cas9), cleaved caspase-3 (Cleaved-cas3), and
α-tubulin was assessed by western blot
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Real-time PCR revealed that CDKN1A, CDKN1B, and
CDKN1C genes, which encode p21(Waf1/Cip1), p27, and
p57, respectively, were significantly increased (Fig. 7c).
Western blot analysis revealed that quisinostat treatment of
the cells resulted in a marked induction of p21(Waf1/Cip1)
and p27 in a dose-dependent manner (Fig. 7d). We also
found that quisinostat treatment of the cells resulted in a
dose-dependent decrease in protein expressions of cyclin
D1 and proliferation cell nuclear antigen (PCNA)
(Fig. 7d). PCNA is the cell proliferation marker.
Effects of quisinostat on other lung cell lines
As our study demonstrated that quisinostat treatment of
A549 cells resulted in p53 up-acetylation, we further ex-
amined the effects of quisinostat on H460—a wild-type
p53-expressed NSCLC cell line—and H1299—a p53-
defective NSCLC cell line. Cell viability assay showed
that quisinostat significantly inhibited cell proliferation of
H460 cells (Fig. 8a) andH1299 cells (Fig. 8b) in dose- and
time-dependent manners. Compared with A549 (Fig. 1b)
and H460, we found that the anti-tumor activity of
quisinostat on H1299 is less effective, especially at 24-
and 48-h time points. It indicated that A549 andH460 cells
are more sensitivity to quisinostat than H1299 cells, which
is p53-defective. Using western blot analysis, we assessed
the effect of quisinostat treatment on the protein expression
of p53 acetylation in H460 cells, and we found that
quisinostat up-acetylated p53 protein at K382/K373 as
well as A549 cells and significantly increased the expres-
sion of p21(Waf1/Cip1) (Fig. 8c). While in H1299 cells, the
expression level of p21(Waf1/Cip1) has not been altered by
quisinostat treatment (Fig. 8d). These results strongly sug-
gest that quisinostat affects p53 activation in NSCLC cells.
In addition, quisinostat also inhibited cell proliferation of
another NSCLC cell line SPCA-1 (Supplement Fig. 2a)
and human bronchial epithelial cell line HBE (Supplement
Fig. 2b).
Discussion
HDACis have shown therapeutic efficacy in solid and
hematological tumors as single agents or in
Fig. 6 GO and KEGG analysis of gene expression profiling. a
Biological process analysis. b Molecular function analysis. c
KEGG pathway analysis. d A549 cells were treated with
quisinostat for 24 h. Protein expression of acetylated p53 (Ac-
p53) and p53 was assessed by western blot
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combinations (Kelly and Marks 2005). So far,
vorinostat (SAHA) in 2006 and romidepsin
(depsipeptide, FK288) in 2009 have been approved
by the US Food and Drug Administration (FDA) for
the treatment of patients with cutaneous T cell lym-
phoma (CTCL) (Grant et al. 2010; Mann et al.
2007). It is reported that the profiles of acetylome
and proteome were changed by HDACi treatment in
NSCLC cells (Wu et al. 2015; Wu et al. 2013),
suggesting that NSCLC cells are sensitive with
HDACi. Furthermore, clinical trials have demonstrat-
ed that HDACis strongly enhance therapy efficacy of
EGFR inhibitors (Gerber et al. 2015) and platinum-
based chemotherapy (Ramalingam et al. 2010) in
NSCLC patients. However, the applicability of
HDACi against patients with NSCLC is still limited.
Quisinostat has been documented to exhibit im-
proved pharmacodynamic properties over HDAC inhib-
itory compounds (Arts et al. 2009). In vitro, quisinostat
has demonstrated a potent anti-proliferative activity
against multiple human tumor cell lines (Arts et al.
2009). In the present study, we showed that quisinostat
significantly inhibited A549 cell proliferation in a
nanomolar concentration in dose- and time-dependent
manners (Fig. 1b). Previous researchers found that
quisinostat induced sustained histone acetylation in nor-
mal tissues as well as tumors (Arts et al. 2009). Here, we
used a pan-anti-acetyllysine monoclonal antibody to
detect acetylated proteins, and we found that quisinostat
extremely changed protein acetylation patterns of A549
cells (Fig. 2a). After quisinostat treatment, acetylated
histones H3 and H4 were significantly increased in a
Fig. 7 Cell cycle distribution of A549 cells in vitro. a, b
Quisinostat induced cell cycle arrest at G1 phase in dose-
dependent manners. Cells were treated with 12.5, 50, and
100 nm of quisinostat for 24 h, respectively, and then, the cells
were harvested to determine cell cycle distribution by flow
cytometry. c CDKN1A, CDKN1B, and CDKN1C were assessed
by real-time PCR. d Protein expression of PCNA, p21, p27,
Cyclin D1, and GAPDH was assessed by western blot. Data are
shown as mean ± SD, n = 3. *p < 0.05, **p < 0.01 versus control
group
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dose-dependent manner (Fig. 2b), suggesting that
quisinostat might affect class I HDACs (HDAC1,
HDAC2, HDAC3, and HDAC8). In addition to his-
tones, acetylated α-tubulin (K40) was also markedly
increased (Fig. 2b), which is a substrate of HDAC6
(Hubbert et al. 2002), indicating that quisinostat could
influence HDAC6 activity. HDAC6 inhibition has been
proposed as the molecular basis for synergism of
HDACi with other anti-cancer agents that act through
proteasome/aggresome deregulation (Bali et al. 2005;
George et al. 2005). So, HDAC6 inhibition in A549
cells might improve quisinostat anti-tumor activity.
Thus, we can confirm that quisinostat affected HDAC
activities and extremely changed protein acetylation
patterns of A549 cells.
Apoptosis is a major mechanism to eliminate can-
cer cells (Green and Kroemer 2004). Our results
showed that quisinostat induced apoptosis in A549
cells (Fig. 5a, b). In the signaling transduction of
apoptosis, cellular mitochondria play pivotal roles
(Jin and El-Deiry 2005). An increase of ROS produc-
tion and, consequently, loss of ΔΨm were reported as
typical phenomena in the process of mitochondria-
mediated early apoptosis (Vaux and Korsmeyer 1999).
Loss of ΔΨm induces the release of pro-apoptotic fac-
tors, such as Cyto c, which is released from the mito-
chondrial inner space to cytosol (van Loo et al. 2002).
Releasing Cyto c can activate caspase-9, which, in turn,
activates executioner caspase-3 via cleavage induction
(Green 2005). Confocal and flow cytometry data indi-
cated that quisinostat significantly increased cellular
ROS generation and destroyed ΔΨm of A549 cells
(Fig. 4). Using western blot analysis, we found that the
protein expression of Cyto c was increased and caspase
cascade was activated by quisinostat (Fig. 5c), suggest-
ing that quisinostat activates mitochondria-mediated in-
trinsic apoptotic pathway. Recently, cellular ROS was
also shown to induce apoptosis by regulating the Bcl-2
family proteins (Li et al. 2004), resulting in increased
expressions of pro-apoptotic proteins and decreased
expressions of anti-apoptotic proteins. Indeed, the ex-
pressions of pro-apoptotic proteins Bax and Bim were
significantly increased, while those of anti-apoptotic
proteins Bcl-2 and Bcl-xl were decreased by quisinostat
treatment (Fig. 5c). These results indicated that
Fig. 8 Effects of quisinostat on H460 andH1299 cells. H460 cells
(a) and H1299 cells (b) were treated with series of quisinostat for
24, 48, or 72 h, and cell viability was evaluated. Mean ± SD of
three experiments performed in triplicate is shown. c, dH460 cells
and H1299 cells were treated with quisinostat for 24 h. Protein
expression of acetylated p53 (Ac-p53), p53, p21, and GAPDH
was assessed by western blot
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quisinostat induced A549 cell apoptosis possibly via a
mitochondrial pathway.
EMT is essential for development and physiological
response to injury (Thiery et al. 2009). However, under
pathological conditions, EMT causes uncontrolled tis-
sue repair and organ fibrosis, as well as the induction of
tumor growth, angiogenesis, and metastasis in the con-
text of cancer progression. Epigenetic mechanisms play
important roles in EMT-associated processes (Kiesslich
et al. 2013), and several classical HDACi completely
suppressed EMT process and cell migration (Chen et al.
2013; Kaimori et al. 2010). We found that quisinostat
could potently upregulate the expression of E-cadherin
(Fig. 3e), which is suppressed by HDAC1 (Ohira et al.
2003); the result is consistent with previous studies (Arts
et al. 2009). In NSCLC, loss of E-cadherin expression is
a critical event associated with cancer metastasis as well
as drug resistance to apoptosis (Kakihana et al. 2009;
Onder et al. 2008). Quisinostat restoring E-cadherin
expression by inhibiting HDAC activity might increase
the sensitivity of NSCLC cells to EGFR inhibitors
(Witta et al. 2006), providing a molecular basis for
combination therapy in patients with NSCLC. We also
found that quisinostat was capable of reducing the ex-
pression of N-cadherin and Vimentin (Fig. 3e), leading
to a significant inhibition in cell migratory potentials
(Fig. 3). Together, our results showed that quisinostat
could significantly inhibit EMT process and suppress
A549 cell migration.
Our results indicated that quisinostat induced cell
apoptosis and inhibited EMT process in A549 cells,
but these pathways are non-specific. To search for
specific pathway of quisinostat on NSCLC cells, we
performed gene expression profiling. Bioinformatics
analysis revealed that quisinostat might affect cell cycle
progression (Fig. 6a) and activate p53 signaling path-
way (Fig. 6c) in A549 cells. A549 expresses wild-type
p53 gene, so two possible mechanisms for quisinostat
via p53 signaling pathway are increased expression of
p53 and activation of p53 functions. In this study, p53
protein level was changed little by quisinostat treatment,
whereas the expression of CDKN1A gene, one down-
stream target gene of p53, was significantly increased
(Fig. 7c), as well as at protein level (Fig. 7d), indicating
that p53 was activated in A549 cells. Acetylation mod-
ification is essential for p53 activity (Tang et al. 2008),
implicating in transcriptional activation (Sakaguchi
et al. 1998), senescence (Pearson et al. 2000), and chro-
mosome fragility (Yu et al. 2000). Up-acetylated p53 is
suggested to play important roles in HDACi treatment
on NSCLC cells (Luo et al. 2000). Western blot data
showed that quisinostat significantly up-acetylated
p53 at K382/K373 sites in A549 cells (Fig. 6d). Up-
acetylation of p53 improved the expression of
p21(Waf1/Cip1) (Fig. 7d) (Szak et al. 2001), which nega-
tively regulates cell cycle progression combined with
other members of CDK inhibitors, including p27 and
p57 (Fig. 7c, d) (Donjerkovic and Scott 2000). Previous
study has demonstrated that p53 acetylation is respon-
sible for p21(Waf1/Cip1) expression (Tang et al. 2006);
substitution of lysine residues 370, 372, 373, 381, and
382 of wild-type p53 with arginine resulted in an 80 %
reduction of p21(Waf1/Cip1) inducibility with HDACi
treatment (Luo et al. 2000). Upregulation of
p21(Waf1/Cip1) has stimulative inhibitory effect on cyclin
D1 expression (Fig. 7d), inhibiting the G1-to-S phase
transition (as assessed by DNA cell cycle analysis,
Fig. 7a). Our results suggest that quisinostat activates
p53 by up-acetylating NSCLC cells and therefore im-
proves the expression of p21(Waf1/Cip1), inducing G1 cell
cycle arrest.
Tomake our conclusions more reasonable, we further
tested the effects of quisinostat on H460 and H1299
cells. H460 is one kind of NSCLC cells with wild-type
p53 gene, while H1299 is a p53-defective NSCLC cell
line. When exposed to quisinostat, the viabilities of
H460 and H1299 cells were both inhibited (Fig. 8a, b).
However, the inhibitory rate of H1299 (Fig. 8b) was
lower than that of H460 (Fig. 8a) and A549 (Fig. 1b) at
the same concentration, suggesting that quisinostat on
H1299 without p53 gene was less effective. Western
blot data showed that quisinostat up-acetylated p53 at
K382/K373 sites in H460 cells (Fig. 8c) as well as A549
cells and significantly increased the expression of
p21(Waf1/Cip1) in a dose-dependent manner (Fig. 8c). In
H1299 cells, the expression level of p21(Waf1/Cip1) has
not been significantly altered by quisinostat treatment
cause of p53 defective (Fig. 8d). Moreover, Luo et al.
found that the apoptosis of H1299 increased when the
cell was transfected with wild-type p53 and treated with
trichostatin A (TSA), a classical HDACi, which inhibits
deacetylation of 373 and/or 382 lysine residues of p53,
causing an increase of p21(Waf1/Cip1) expression (Luo
et al. 2000). That explains a part of reasons why A549
and H460 are more sensitive to quisinostat. Taken to-
gether, these results indicate that p53 acetylation is
crucial for quisinostat-mediated anti-tumor activity in
lung cancer.
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In summary, quisinostat exerted strong anti-tumor
effects on NSCLC cells related to induction of apoptosis
via mitochondrial apoptotic pathways. With inhibition
of EMT process, quisinostat significantly reduced cell
migration. Up-acetylation of p53 at 382/373 lysine res-
idues has a significant, dose-dependent effect on im-
proving p21(Waf1/Cip1), inducing G1 phase arrest. The
detailed unraveling of quisinostat-mediated effects will
be helpful for a targeted use in NSCLC and for further
selection of suitable combination partners.
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